# Clinical Trials Data KIT - Document 53

# Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

## Clinical Trial: https://clinicaltrials.gov/study/NCT01532076

"eligibilityCriteria": "Inclusion Criteria:\n\nPresentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:\n\n\* indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS\u00ae, Synthes, Switzerland) after low energy trauma\n\n \* displacement of more than 1 cm between fragments and/or\n \* angulation of 45\u00b0 or more between the fragments and/or\n \* dislocation of the greater tuberosity of 5 mm or more and/or\n \* patient specific factors like high functional demand etc\n\* age \\> 50 years\n\* postmenopausal status (i.e. 12 continuous month without menstruation)\n\* informed consent in surgery and study participation\n\nExclusion Criteria:\n\n\* Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) \\<24, schizophrenia, major depression)\n\* Pathological fractures caused by other conditions\n\* Fracture-related nerve injury\n\* Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)\n\* BMI \\<20 kg/m2\n\* Known hypersensitivity to one of the graft components\n\* Participation in a clinical trial within 3 month before enrolment",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "50 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention anything about KIT gene mutations as an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not have any of the exclusion criteria to be eligible.